SecBot SecBot
SECBOTREPLAY Home › Report › KYMR

KYMR · Atlas Venture, a founding VC investor in Kymera Therapeutics, has filed…

Kymera Therapeutics, Inc. · 144 filed Jun 29, 2026 at 17:51 ET

At the news

NEUTRALIMPACT 4/10

144 filed Jun 29, 2026 at 17:51 ET

Atlas Venture, a founding VC investor in Kymera Therapeutics, has filed two Form 144 notices to sell a combined 76,650 shares of common stock valued at approximately $8.3M (~0.09% of market cap). These filings follow a remarkable 9 consecutive days of heavy Atlas Venture selling (April through late June 2026) totaling over 1.6 million shares worth ~$157M, as disclosed in the same filing's recent transaction history. The selling is part of a systematic, pre-planned secondary distribution by a venture fund that owned the shares since a 2020 private placement and is well past its standard lock-up. While the 76,650 share amount is small relative to the prior week's pace (>1.4M shares sold June 17-26), the filings confirm Atlas continues to monetize its position in an orderly manner. This does not reflect management's view of the business, Kymera has 93% analyst buy ratings and a $9.4B market cap, but the persistent supply overhang is a real technical factor.

  • Atlas Venture Fund X, L.P. filed Form 144 to sell 66,177 shares at ~$7.16M.
  • Atlas Venture Opportunity Fund I, L.P. filed Form 144 to sell 10,473 shares at ~$1.13M.
  • Combined proposed sale: 76,650 shares worth ~$8.29M (0.09% of $9.4B market cap).
  • Filings disclose Atlas Venture funds sold over 1.6 million shares between June 17-26, 2026 totaling ~$157M.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access